Edesa Biotech, Inc. — Form 10-Q summary
Reporting period: Quarter and six months ended June 30, 2019. Financial statements are unaudited and presented in U.S. dollars. The June 7 reverse acquisition means the period includes a major change in the business and capital structure; comparisons with 2018 should be read in that context.
Business context
Edesa is a clinical-stage biopharmaceutical company developing therapies for dermatological and gastrointestinal conditions. Its lead candidate, EB01, is a topical sPLA2 inhibitor for chronic allergic contact dermatitis (ACD); the company planned a Phase 2B study. The FDA accepted EB01’s investigational new drug application in November 2018. Edesa also described plans to evaluate EB02 for hemorrhoids and to pursue additional product opportunities. It has not generated meaningful product revenue.
On June 7, 2019, Stellar Biotechnologies acquired Edesa Biotech Research in a reverse acquisition, with Edesa treated as the accounting acquirer. The company changed its name from Stellar to Edesa and effected a 1-for-6 reverse share split. Management intended to sell or wind down Stellar’s legacy assets and operations over the following 18 months.
Key financial metrics
| Metric | Three months ended June 30, 2019 | Six months ended June 30, 2019 |
|---|---|---|
| Revenue | $500 | $500 |
| Operating expenses | $1.321 million | $1.862 million |
| Operating loss | $1.320 million | $1.861 million |
| Net loss | $1.294 million | $1.823 million |
| Basic and diluted loss per share | $0.30 | $0.48 |
Cash flow and liquidity: Six-month operating cash use was $3.519 million, compared with $0.688 million in 2018. Investing cash flow was positive $6.405 million, including $6.389 million of cash acquired in the reverse acquisition. Cash rose by $2.996 million from year-end to $6.363 million at June 30. Current assets were $7.124 million, current liabilities $1.015 million, working capital $6.109 million, and shareholders’ equity $6.213 million. The balance sheet reports no interest-bearing debt; total liabilities shown were current accounts payable and accrued liabilities of $1.015 million.
Gross margin is not meaningful given only $500 of revenue and the company’s development-stage operations. The filing does not report a product-sales margin.
Changes versus the comparable 2018 periods
- Six-month net loss increased to $1.823 million from $0.827 million; quarterly net loss increased to $1.294 million from $0.412 million.
- Six-month R&D expense rose to $0.615 million from $0.578 million, primarily reflecting EB01 clinical research, patent, and personnel costs. Quarterly R&D expense was $0.503 million versus $0.298 million.
- Six-month general and administrative expense rose to $1.247 million from $0.275 million, mainly due to reverse-acquisition legal and professional fees, personnel, and new public-company costs. Quarterly G&A was $0.818 million versus $0.124 million.
- The six-month cash-use comparison was affected by working capital movements, including a $1.339 million cash outflow from accounts payable and accrued liabilities.
Outlook, commitments, and risks
Management expected continued operating losses and said it planned to fund operations over the next 12 months with cash and investments on hand. It may also seek equity or debt financing, licensing or collaboration arrangements, or other strategic transactions; no committed external funding source was identified. The company’s ability to advance candidates depends on clinical outcomes, regulatory decisions, access to capital, and third-party suppliers and trial providers.
Disclosed future commitments included approximately $498,000 of minimum lease payments and $2.342 million of contracted clinical research and other service-provider payments. Separate license agreements may require milestone payments of up to $18.6 million and $18.5 million, respectively, plus royalties or sublicensing payments if applicable. These are contingent on specified events and are not presented as current liabilities. The filing also identifies clinical, regulatory, financing, intellectual-property, manufacturing, patient-enrollment, currency, and commercialization risks. No material legal proceedings outside the ordinary course were reported.
Other notable items: all Class A preferred shares and accrued return converted into 3,376,112 common shares upon the transaction; the filing reports 7,504,468 common shares outstanding at June 30 and August 14, while additional shares and replacement options were issued on July 26 under a post-closing adjustment. Management concluded disclosure controls were effective as of June 30. The company planned to adopt the lease accounting standard on October 1, 2019 and was assessing its impact.
Important facts for investors to verify
- EB01 Phase 2B study status, timing, enrollment, and funding needs; the filing describes plans, not trial results.
- Whether the stated 12-month funding plan remains adequate given operating cash use and contracted clinical obligations.
- Post-closing share count, options, warrants, and potential dilution, including the July 26 adjustment.
- Progress and costs of winding down legacy Stellar operations, and any contingent license milestones or royalties.
- Regulatory feedback on the clinical evidence and trial design needed to support any future marketing application.